Probenecid impairment of acetaminophen and lorazepam clearance. Direct inhibition of ether glucuronide formation ,
, J. Pharmacol. Exp. Ther, vol.234, pp.345-349, 1985.
, , pp.322-334
Viral resistance, clinical experience. Scand, J.Infect.Dis, vol.47, pp.155-164, 1985. ,
Acyclovir prodrugs: the road to valaciclovir, Drugs Fut, 1993. ,
In vitro susceptibility of varicella zoster virus to acyclovir ,
, Antimicrob. Agents Chemother, vol.18, pp.443-447, 1980.
Overview of acyclovir pharmacokinetic disposition in adults and children, Am.J.Med, vol.73, pp.186-192, 1982. ,
A Pharmacokinetics of cimetidine after single doses and during continuous treatment, Clin.Pharmacokinet, vol.6, pp.306-315, 1981. ,
Cephalosporin-probenecid drug interactions, Clin. Pharmacokinet, vol.24, issue.4, pp.289-300, 1993. ,
Inhibition of renal creatinine secretion by cimetidine in humans, Renal Physiol, vol.5, pp.27-30, 1982. ,
Metabolic disposition of BW256U87, the L-valyl ester of acyclovir, in the rat, Antiviral Res, vol.17, 1992. ,
Purification and characterization of an enzyme from rat liver that hydrolyses 256U87, the L-valylester prodrug of acyclovir (ZOVIRAX®), Antiviral Res, vol.20, 1993. ,
In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir, Diag Microbiol Infect Dis, vol.6, pp.255-261, 1987. ,
Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir, JAntimicrob, vol.18, pp.103-112, 1986. ,
Clinical pharmacokinetics ofprobenecid, Clin. Pharmacokinet, vol.6, pp.135-151, 1981. ,
The clinical significance of antiviral drug resistance, Res. Viral, vol.143, pp.115-148, 1992. ,
Disposition of intravenous radioactive acyclovir, Clin. Pharmacol. Th er, vol.3, issue.0, pp.662-672, 1981. ,
Biotransformation of acyclovir to 9-carboxymethoxymethylguanine, Fed. Proc, vol.41, p.1733, 1982. ,
Pharmacokinetics of acyclovir after intravenous and oral administration, J.Antimicrob.Chemother, vol.12, pp.29-37, 1983. ,
,
Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex, Clin. Pharmacol. Ther, vol.46, pp.494-500, 1989. ,
Species differences in the metabolism and disposition of antiviral nucleoside analogs: 1-Acyclovir, Antiviral Chem.Chemother, vol.3, issue.1, pp.1-8, 1992. ,
, Drugs five years later : Acyclovir. Ann.!nt.Med, vol.107, pp.859-874, 1987.
Effect of cimetidine on renal function in normal man, Clin.Pharmacol.Ther, vol.24, issue.1, pp.76-83, 1978. ,
Carrier mediated transport of the organic cation procainamide ethobromide by isolated rat liver parenchymal cells, J. Pharmacol. Exp. Ther, vol.206, pp.595-606, 1978. ,
,
, Selectivity of action of an antiherpetic agent, Proc. Nat!, vol.9
, , vol.74, pp.5716-5720, 1977.
The biochemistry and mechanism of action of acyclovir, J.Antimicrob.Chemother, vol.12, pp.9-17, 1983. ,
,
Herpes simplex virus resistant to acyclovir : a study in a tertiary care center ,
, Ann.Intern.Med, vol.112, pp.416-422, 1990.
Inhibition ofHerpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9, J. Viral, vol.32, issue.2, pp.72-77, 1979. ,
Metabolism of acyclovir in virus infected and uninfected cells, Antimicrab. Agent Chemather, vol.20, issue.4, pp.518-524, 1981. ,
Acyclovir triphosphate is a suicide inactivator of the Herpes simplex virus DNA polymerase, J.Bial.Chem, vol.259, issue.15, pp.9575-9579, 1984. ,
Effect of probenecid on the renal and non-renal clearance of zidovudine and its distribution in cerebrospinal fluid in the rabbit, J.Phann.Sci, vol.78, pp.716-722, 1989. ,
La résistance clinique aux antiviraux. La lettre de l, Infectialague, vol.7, issue.8, pp.261-268, 1992. ,
Valaciclovir (BW256U87): The L-valyl ester of acyclovir, J.Med. Viral, 1993. ,
Impairment ofhepatic uptake ofrifamycin antibiotics by probenecid, and its therapeutic implications, Lance!, vol.2, pp.1401-1405, 1973. ,
Probenecid and zidovudine metabolism, Lancet, vol.26, pp.473-475, 1989. ,
,
Regional blood-brain lactate influx, Brain Res, vol.614, issue.1-2, pp.164-170, 1993. ,
,
Effect of renal failure on the pharmacokinetics of acyclovir, Am.J.Med, 1982. ,
,
Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans ,
, Antimicrob.Agents Chemother, vol.21, pp.804-807, 1982.
Clinical pharmacokinetics of acyclovir, Clin.Pharmacokinet, vol.8, issue.3, pp.187-201, 1983. ,
Weighted serum pools in comparison to the trapezoïdal rule for estimating AU Cs for ethinyl oestradiol, Eur.J. Clin.Pharmacol, vol.46, pp.77-81, 1994. ,
The Extra Pharmacopoeia 30th Edition ,
Acyclovir for prevention of cytornegalovirus infection and disease after allogeneic rnarrow transplantation ,
, NEngl.J.Med, vol.318, pp.70-75, 1988.
Phosphorylation of acyclovir (acycloguanosine) rnonophosphate by GMP kinase, J.Biol.Chem, vol.255, pp.7204-7207, 1980. ,
Phosphorylation of acyclovir diphosphate by cellular enzymes ,
, Biochem.Pharmacol, vol.31, pp.3879-3884, 1982.
Effect of cimetidine on renal and hepatic drug elimination : studies with triamterene, Clin.Pharmacol. Ther, vol.40, pp.400-407, 1986. ,
Acyclovir-An updated review of its antiviral activity, pharrnacokinetic properties and therapeutic efficacy, Drugs, vol.37, pp.233-309, 1989. ,
,
, hydroxyethoxymethyl)guanine activity against viruses of the herpes group, Nature, vol.272, issue.9, pp.583-585, 1978.
Sequential intravenous and twice daily oral acyclovir for extended prophylaxis of Herpes simplex virus infection in marrow transplant patients, Transplantation, vol.43, issue.5, pp.654-658, 1987. ,
Effect of probenecid on the formation and elimination of acyl glucuronides : studies with zomepirac, Clin.Pharmacol. Ther, vol.38, pp.121-127, 1985. ,
Drug interactions with cimetidine, Clin.Pharmacokinet, vol.7, pp.23-41, 1982. ,
Cimetidine-procainamide pharmacokinetic interaction in man : evidence of competition for tubular secretion of basic drugs, Eur.J. Clin.Pharmacol, vol.25, pp.339-345, 1983. ,
Pharmacokinetic interactions of cimetidine, 1987. ,
, Clin.Pharmacokinet, vol.12, pp.321-366, 1987.
Reduction of metformin renal tubular secretion by cimetidine in man, Br. J. Clin. Pharmacol, vol.23, pp.545-551, 1987. ,
The effects of salicylate and probenecid on the cerebrospinal fluid transport ofpenicillin, aminosalicylic acid and iodide, J.Pharmacol.Exp.Ther, vol.188, p.55, 1974. ,
Inhibition of cellular a and virally induced deoxyribonucleic acid polymerase by the triphosphate of acyclovir ,
, , vol.18, pp.741-745, 1980.
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells, Nature, vol.358, pp.162-164, 1992. ,
Selectivity of the cimetidine-induced alterations of the renal handling of organic substrat es in humans. studies with anionic, cationic and zwitterionic drugs, J.Pharmacol.Exp.Ther, vol.236, pp.481-487, 1986. ,
Treatment of cytomegalovirus pneumonia with high-dose acyclovir, Acyclovir Symposium Am.J.Med, vol.73, pp.249-255, 1982. ,
,
Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating singleand multiple-dose administration to normal volunteers, Clin. Pharmacol. Ther, vol.54, issue.6, 1993. ,
The mechanism of action, pharmacokinetics and toxicity of acyclovir-a review, J.Jnjection, vol.6, pp.3-9, 1983. ,
Acyclovir inhibition of Epstein-Barr virus replication, P 'Jc.Natl.AcadSci. USA, vol.77, issue.9, pp.5163-5166, 1980. ,
Persistent Herpes simplex virus infection and mechanisms of virus drug resistance ,
, Eur.J.Clin.Microbiol.Inject.Dis, vol.8, issue.8, pp.671-680, 1989.
Organic amon transport by basal-lateral membranes : effect of p-aminohippurate and furosemide on each other's transport, Pharmacology, vol.37, pp.268-76, 1988. ,
Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir, Lancet, vol.2, pp.706-708, 1983. ,
Oral valaciclovir (V ALTREX ®) produces acyclovir exposure comparable to that following intravenous acyclovir in allogeneic BMT patients, 1994. ,
,
Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities, Biochem.Pharmacol, vol.30, issue.22, pp.3071-3077, 1981. ,
Pharmacokinetics and tolerance of acyclovir, a new anti-herpes virus agent ,
, Antimicrob. Agents Chemother, vol.21, pp.393-398, 1982.
One year acyclovir suppression of frequently recurrent genital herpes : a study of efficacy, safety, virus sensitivity and antibody response, Scand.Jlnfect.Dis, vol.78, pp.33-39, 1991. ,
Occurence and characterization of acyclovir-resistant herpes simplex virus isolates : report on a two-year sensitivity screening survey, J.Med. Viral, vol.36, issue.1, pp.1-12, 1992. ,
Acyclovir : a review of its pharmacocynamic properties and therapeutic efficacy, Drugs, vol.26, pp.378-438, 1983. ,
Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in Herpes simplex virus-infected and uninfected cells, Biochem.Pharmacol, vol.34, issue.7, pp.1049-1056, 1985. ,
Mécanismes d'action et de résistances aux agents antiviraux ,
, Infectiologue, vol.6, issue.15, pp.507-510, 1991.
Monitoring the safety of antivirals. The example of the acyclovir experience ,
, Am.J.Med, vol.85, pp.116-122, 1988.
,
Bioavailability of cimetidine in man, Gastroenterology, vol.74, pp.360-365, 1978. ,
Acyclovir: a decade later, New Engl.J.Med, vol.327, issue.11, p.782, 1992. ,
, ANNEXE, vol.5, 1994.
, Elle consiste à pooler le plasma des différents prélèvements d'un même sujet avec des volumes
, En effet, d'un point de vue mathématique, l'aire d'un trapèze est calculée par la formule
, /2 b x (Il + 12), où b est la base du trapèze et 11 et 12 les longeurs respectives de chacun des 0
, L'idée du pool plasmatique pondéré consiste à mélanger les prélèvements. avec des volumes proportionnels aux coefficients (poids) correspondants. La concentration de ce mélange est proportionnele à l'AUC calculée par la méthode des trapèzes. Multipliée par 4, c'est une estimation de